Two more phase 3 trials of Merck’s challenger to Pfizer’s Prevnar 13 have met their immunogenicity endpoints. The results suggest the V114 vaccine provides broader protection from pneumococcal ...

Pfizer Inc. PFE on Wednesday reported positive Phase 2 data for its investigational 25-valent pneumococcal conjugate vaccine candidate. The study showed strong immune responses in infants compared ...

There are four pneumococcal vaccines available. Different vaccines are recommended depending on age and medical status. The Food and Drug Administration (FDA) has licensed three pneumococcal conjugate ...

One of Merck’s next-generation pneumococcal vaccines has sailed through a mid-stage trial and is being readied for a phase 3 study next month. V116—one of three pneumococcal vaccines in Merck’s ...

The Food and Drug Administration has approved Merck’s new pneumococcal vaccine in adults aged 18 years and older. The drug, brand name Vaxneuvance, protects against 15 strains of bacteria that can ...

Pfizer announced topline data from one of its phase 3 studies for 20-valent pneumococcal conjugate vaccine (20vPnC) for the prevention of invasive disease and pneumonia caused by Streptococcus ...